|
|
 |
|
Viewing report
|
|
|
|
Growth Strategies In Generics: Innovative And Aggressive Strategies And Their Impact On Branded Pharmaceuticals
Business Insights, July 2004, Pages: 172
Strengthen your competitive position by understanding the growth strategies of generic drug companies and the impact that this will have on both the generic and the branded pharmaceutical sector in the future, with the help of our latest management report...
‘Growth Strategies in Generics: Innovative and aggressive strategies and their impact on branded pharmaceuticals’ is a report which assesses the growth prospects of generic drugs in Europe and the US. The report gives a detailed analysis of the impact of new legislation, the strategies of the key players and market pressures on the generic and branded drug sectors.
The generics market in both Europe and the US is highly dynamic. Growth is high, and forecast to continue strongly in the next five years as penetration of generics in pharmaceutical sales is still comparatively low in key markets such as the UK and France. At the same time, the distinctions between some generics companies and traditional, R&D-led pharmaceutical companies are blurring as generics companies move up-stream and invest in R&D while pharmaceutical companies such as Novartis, Sanofi and Merck retain successful generic subsidiaries.
However, market saturation threatens to erode profit margins for generics companies as prices are forced lower, while manufacturers outside Europe and the US take an increasing market share. Identify the key trends in manufacturing, marketing, competitive structure, profit margins and intellectual property in Europe and the US with the help of our latest report.
“One key question is whether the new Bolar clause will have any significant impact on the rate at which generic
copies are launched in Europe post patent expiry or the speed to market of new copies. Those companies that are intent on being in the market on day one have already developed relationships with developers in countries not affected by product patent legislation either in the EU or outside it, e.g India and Iceland...”
Key findings in this report
- Indian manufacturers represent the greatest threat to the existing generics market, and will force both mainstream pharmaceutical companies and established generics companies to explore alliances and acquisitions there.
- Generic drug sales are forecast by the majority of branded drug and generic drug company executives to be above 5%. One third of all executives forecast growth above 10%.
- On balance, new legislation in both the EU and the US has been more beneficial to generics companies, lowering barriers to entry and speeding up the approvals process.
- The distinction between established generics companies and mainstream pharmaceutical companies is blurring as companies such as Teva and Ranbaxy increase their investment in R&D in a bid to push their product portfolios upstream.
- Biogenerics will reach Europe before the US due to recent legislative changes. Lower regulatory barriers have meant that Eastern Europe is an area of expertise for biogenerics.
“The southern European generics markets of Italy, Spain and France exhibited strong growth in 2002, but still contributed less than 3.6% to global generics sales. According to a statement from the French generic industry association GEMME in September 2003 this situation had improved and generics accounted for 5% by value and 10% by volume – this clearly still leaves plenty of room for expansion...”
The answers to your questions...
1. What will be the impact of Indian and Chinese manufacturers on established generic drug manufacturers?
2. How will each new piece of legislation in Europe and the US affect the growth strategies of generic and branded pharmaceutical companies?
3. How are generics companies seeking to diversify and develop in the future?
4. What are the key trends that will drive generics growth in Europe and the US?
5. What successful strategies are generics companies using and how are these evolving in the face of increasing market pressures?
6. Which country markets will see the highest growth and what are the most attractive therapy areas for generics companies to target?
Top reasons to order your copy today...
- Understand the growth strategies of generics companies, the decisions driving their expansion and the challenges they face.
- Assess how generics companies are adapting to competitive pressures and blurring the distinctions with mainstream pharmaceutical companies.
- Learn how pricing of generics will change in the next five years and the impact this will have on the market.
- Benchmark your opinions on how the generics market will develop against senior executives from both generic and mainstream pharmaceutical companies.
- Identify the risk posed by fast growth new entrant manufacturers in China, India, Eastern Europe and Latin America.
'A review of the portfolios of the top 40 pharmaceutical companies shows that products with total sales of $137 billion in 2002 will have lost primary US patent protection by 2008. This represents over 50% of the $235 billion in total product sales generated by these 40 companies in 2002. Looking ahead, 2006 could present a key opportunity for generics companies to profit from patent expires, as blockbuster drugs with 2002 sales of over $16 billion face expiry of their US patent protection...'
Customers who bought this item also bought
Generics Series: Generics Trends in the Seven Major Markets and Beyond
Generic Series: An Introduction To The Canadian Generics Market - Key Trends And Leading Companies Shaping The Market
Generics Series: Authorized Generics Analysis
New Dynamics and Challenges in the Generics Market 2007
Indian Generics, 2008-2012: The Growing Threat to Westernised Markets
Generics Series: Key trends and events in the 7 major markets
Generics Erosion Patterns in the U.S. Market
World Generics and Biogenerics Markets
Watson: PharmaVitae Generics Profile
The European Generics Outlook: A Country-By-Country Analysis Of Developing Market Opportunities And Revenue Defense Strategies
Mylan: PharmaVitae Generics Profile
Pharmavitae Generics - Teva
|
|
|
|
